EMA Recommends ALUNBRIG for the Treatment of Non-Small Cell Lung Cancer
oracast / Pixabay

EMA Recommends ALUNBRIG for the Treatment of Non-Small Cell Lung Cancer

The European Medicines Agency has recently released their positive opinion of ALUNBRIG, which is a treatment for anaplastic lymphoma kinase+ (ALK+) non-small cell lung cancer (NSCLC). They have recommended this…

Continue Reading EMA Recommends ALUNBRIG for the Treatment of Non-Small Cell Lung Cancer

Idiopathic Thrombocytopenic Purpura Took the Life of a Teen, but Her Organs Saved the Lives of Others

Abbey Luffman was a 16-year-old from Owego, New York excited about getting her learner's permit. She was also very generous; she didn't even hesitate to check the box for organ…

Continue Reading Idiopathic Thrombocytopenic Purpura Took the Life of a Teen, but Her Organs Saved the Lives of Others
The Importance of Diagnoses: Living with Lyme Disease and Hashimoto’s Disease
source: pixabay.com

The Importance of Diagnoses: Living with Lyme Disease and Hashimoto’s Disease

Obtaining a diagnosis for a rare disease tends to be very difficult. Doctors do not immediately expect that rare conditions are causing one's symptoms; they blame more common conditions first.…

Continue Reading The Importance of Diagnoses: Living with Lyme Disease and Hashimoto’s Disease
Ethnobotanical Medicine is Proven to be an Effective Treatment for Lyme Disease
https://pixabay.com/en/thistles-flower-marianum-plants-1039039/

Ethnobotanical Medicine is Proven to be an Effective Treatment for Lyme Disease

Lyme disease is the most common vector-borne disease, and it has become more prominent due to climate change and urban developments spreading further into wooded areas. Treatment is typically effective…

Continue Reading Ethnobotanical Medicine is Proven to be an Effective Treatment for Lyme Disease
ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma
source: pixabay.com

ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma

CSL Behring has recently received the Orphan Drug designation for Privigen for the treatment of systemic scleroderma. Privigen has also been granted the Fast Track designation. This therapy has been…

Continue Reading ICYMI: Privigen Granted Orphan Drug Designation For Treatment of Systemic Scleroderma
Study: Results from Phases II/III of Clinical Trial of Gantenerumab, a Treatment for Alzheimer’s Disease
source: pixabay.com

Study: Results from Phases II/III of Clinical Trial of Gantenerumab, a Treatment for Alzheimer’s Disease

Roche has recently released the results of the latest phases of their study of gantenerumab, which is a treatment of a rare form of Alzheimer's disease. This form, which is…

Continue Reading Study: Results from Phases II/III of Clinical Trial of Gantenerumab, a Treatment for Alzheimer’s Disease